Trial Profile
Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 03 Aug 2020 Status changed from recruiting to discontinued.
- 16 May 2018 New trial record